The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.




AMA submission to the Therapeutic Goods Administration - proposed amendments to the Poisons Standard – June 2020

19 May 2020

In this submission, the AMA provides feedback to the medicine scheduling proposals for June 2020. The AMA does not oppose the proposed changes to oxymetazoline, clotrimazole, cumyl-pegaclone, nicotine, methylisothiazolinone and methylchloroisothiazolinone, and isothiazolinones. The AMA supports increased access to eletriptan. The AMA opposes the proposed changes to sildenafil, ibuprofen, and cannabidiol.

Published: 19 May 2020